Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ciprofibrate→

Ciprofibrate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
52214-84-3
Molecular formula
C13H14Cl2O3
Molecular weight
289.15 g/mol
Drug class
Fibrate lipid-modifying agentperoxisome proliferator-activated receptor alpha (PPARα) agonist
Mechanism of action
Activates PPARα, increasing lipoprotein lipase activity and fatty-acid oxidation and reducing hepatic production of triglyceride-rich lipoproteins, lowering triglycerides and modifying HDL levels.
Indications / reported uses
  • Treatment of mixed dyslipidaemia and hypertriglyceridaemia in adults when dietary and lifestyle measures are inadequate and where ciprofibrate is authorised; monitor muscle and liver safety, particularly with statin co-administration

Sources: NLM MeSH — Ciprofibrate · PubMed — Ciprofibrate PPAR alpha pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ciprofibrate Environmental Risk Assessment (ERA) (the Ciprofibrate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.